Bisphenol A

Bisphenol A (BPA) is a chemical that is mainly used in combination with other chemicals to manufacture plastics and resins. For example, BPA is used in polycarbonate, a high performance transparent, rigid plastic. Polycarbonate is used to make food containers, such as returnable beverage bottles, infant feeding (baby) bottles, tableware (plates and mugs) and storage containers. Residues of BPA are also present in epoxy resins used to make protective coatings and linings for food and beverage cans and vats. BPA can migrate in small amounts into food and beverages stored in materials containing the substance. 

Topics: Completed work

2016 - EFSA set up a working group of international experts to evaluate new scientific evidence on the potential effects of BPA on the immune system. EFSA is conducting the review following publication of a report by the Dutch National Institute for Public Health and the Environment, which raises concerns about the effects of BPA on the immune system of fetuses and young children.

EFSA published its latest comprehensive re-evaluation of BPA exposure and toxicity, in January 2015.

EFSA completed its first full risk assessment of BPA in 2006. Since then, the Authority and its scientific panels have considered hundreds of scientific publications in peer-reviewed scientific journals as well as reports from studies submitted by industry. EFSA reviewed new scientific information on BPA in 2008, 2009, 2010 and 2011. Its comprehensive re-evaluation was published in January 2015.

Past milestones

2015 - EFSA’s most recent review of BPA exposure and toxicity concluded that BPA poses no health risk to consumers of any age group (including unborn children, infants and adolescents) at current exposure levels.

2014 - EFSA presented the second part of its draft opinion relating to the human health risks posed by exposure to BPA. This was also accompanied by an eight-week public consultation.

2013 - EFSA held a public consultation on the first part of its draft scientific opinion, specifically on its assessment of consumer exposure to BPA. EFSA provisionally concluded that for all population groups diet is the major source of exposure to BPA and exposure is lower than previously estimated by EFSA.

2012 - EFSA’s experts decided to undertake a full re-evaluation of the human risks associated with exposure to BPA through the diet, also taking into consideration the contribution of non-dietary sources to the overall exposure to BPA. The new opinion would review all the available data and scientific studies on dietary exposure published since EFSA’s 2006 Opinion. The Panel would further evaluate uncertainties about the possible relevance to human health of some BPA-related effects observed in rodents at low dose levels.

2012 - EFSA tackled the issue of low dose effects in toxicology and risk assessment at its dedicated Scientific Colloquium, with the participation of international experts, taking place in Parma on 14-15 June 2012.

2011 - The CEF Panel published a Statement addressing reports on BPA published by the French Health and Safety Agency (ANSES) in September 2011. In its Statement, the CEF Panel considered that overall the information in the ANSES report on health effects of BPA did not change the views expressed by the Panel in its earlier opinions on the safety of BPA. Following an exchange of information between EFSA and ANSES, it was concluded that ANSES’ work was limited to hazard identification while EFSA had carried out a full risk assessment of BPA in 2006.

However, the CEF Panel confirmed that it would reconsider its opinion following further evaluation of new studies and when new data from the low dose studies ongoing in the United States become available.

2010 - EFSA updated its advice on BPA in September 2010. Following a detailed and comprehensive review of recent scientific literature and studies on the toxicity of BPA at low doses, the CEF Panel concluded they could not identify any new evidence which would lead them to revise the TDI for BPA of 0.05 mg/kg body weight set by EFSA in its 2006 opinion. The Panel also stated that the data available did not provide convincing evidence of neurobehavioural toxicity of BPA.

One Panel member expressed a minority opinion, considering that some recent studies pointed to uncertainties regarding adverse health effects below the level used to determine the current TDI.

2010 - EFSA received a further related request from the Commission to also take into account any new scientific evidence available that might affect the conclusions of the previously adopted opinions on BPA and to liaise closely with EU Member State risk assessment bodies on this issue. Subsequently EFSA held a meeting with national experts on BPA from EU Member States and representatives of the Commission, in which members of EFSA’s CEF Panel outlined a new draft opinion on BPA.

2009 - EFSA received a request from the Commission to assess the relevance of a new study by Stump on possible neurodevelopmental effects of BPA and, if necessary, to update the existing TDI accordingly. The study had  been commissioned by the American Chemistry Council to address safety concerns raised by the Canadian government, which had introduced legislation to ban the use of polycarbonate in baby feeding bottles.

2008 - EFSA addressed the differences in the ability of infants and adults to clear BPA from the body. EFSA confirmed that exposure to BPA was well below the then TDI of 0.05 mg/kg bw for both adults and newborns. After exposure to BPA the human body rapidly metabolises and eliminates the substance. This is also true for newborns who can clear BPA at levels far in excess of the TDI. In its evaluation, EFSA took into account both the previous and the most recent information and data available from all sources (industry as well as peer-reviewed scientific literature).

2008 - The European Commission asked EFSA to assess the conclusions of a study by Lang et al. (Journal of the American Medical Association, 16 September 2008) that suggested a link between levels of urinary BPA and increased occurrence of heart disease and diabetes. In a statement adopted in October 2008, EFSA noted that the study did not include any information on long-term exposure to BPA which would be needed to establish a correlation between BPA and the development of the chronic medical conditions in question. Therefore the study did not provide proof of a causal link between BPA and these health conditions.

2006 - EFSA completed its first full risk assessment of BPA in 2006 and set a Tolerable Daily Intake (TDI) of 0.05 milligrams/kilogram of body weight (mg/kg bw/day) for this substance. At the same time, EFSA also evaluated intakes of BPA through food and drink, for adults, infants and children and found that they were all below the TDI.

EFSA adopts scientific opinions and provides scientific advice for risk managers on the safety of BPA when used in materials which come into contact with food. This work is carried out by EFSA’s Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF).

As part of its safety evaluations of food contact materials EFSA establishes, when possible (i.e. when sufficient information is available), a Tolerable Daily Intake (TDI) for each substance. The TDI is an estimate of the amount of a substance that people can consume on a daily basis during their whole life without any appreciable risk to health. TDIs are usually expressed in mg or µg per kg of body weight per day (mg/kg bw/day).

EFSA liaises closely with European and national bodies engaged in BPA evaluations as well as with other scientific experts on studies currently in progress.

BPA is permitted for use in food contact materials in the European Union (EU) under Regulation 10/2011/EU, relating to plastic materials and articles intending to come into contact with foodstuffs. In January 2011, the European Commission adopted Directive 2011/8/EU, prohibiting the use of BPA for the manufacture of polycarbonate infant feeding bottles.

BPA is also permitted for food contact use in other countries such as the USA and Japan.

Completed work
E.g., 07/26/2016
E.g., 07/26/2016

Pages

1. What is bisphenol A (BPA) and how is it used?

BPA is a chemical compound used in the manufacture of polycarbonate (PC) plastics, epoxy resins and other polymeric materials, as well as for certain paper products. PC is used in food contact materials present in food and liquid containers such as tableware (plates and mugs), microwave ovenware, cookware, reservoirs for water dispensers and non-food applications such as toys and pacifiers with PC shields. BPA-based epoxyphenolic resins are used as protective linings for food and beverage cans and as a coating on residential drinking water storage tanks.

BPA is also used in a number of non food-related applications, including epoxy-resin based paints, medical devices, dental sealants, surface coatings, printing inks and flame retardants. A widespread application of BPA is in thermal paper commonly used for till/cash register receipts. As a result of abrasive contact with epoxy-based floorings, adhesives, paints, electronic equipment and printed circuit boards BPA may also be present in household dust.

2. How can BPA get into our diet?

Small amounts of BPA can migrate from food contact materials into foods and beverages.

3. Is BPA from food and other sources a health concern?

EFSA’s latest comprehensive re-evaluation of BPA exposure and toxicity was published in January 2015. EFSA’s scientific experts concluded that BPA poses no health risk to consumers of any age group (including unborn children, infants and adolescents). Exposure from the diet or from a combination of sources (diet, dust, cosmetics and thermal paper) is considerably under the safe level (“tolerable daily intake” or TDI) of BPA in food: four micrograms per kilogram of body weight per day (µg/kg of bw/day). The highest estimates for dietary exposure and for exposure from a combination of sources (called “aggregated exposure”) are three to five times lower than the TDI.

The TDI is an estimate of the amount of a substance (expressed on a body weight basis) that can be ingested daily over a lifetime without appreciable risk.

4. Has EFSA carried out previous safety reviews of BPA?

EFSA first assessed the safety of BPA for consumers in 2006. The Authority provided additional scientific advice on BPA in 2008, 2009 and significantly in September 2010 when it updated its opinion on BPA following a detailed and comprehensive review of new scientific studies on the toxicity of BPA at low doses. In November 2011, EFSA published a statement on BPA following publication of a report on health effects of BPA issued by the French food safety agency (ANSES).

 

 

EFSA’s 2015 risk assessment of BPA in foodstuffs

5. Why did EFSA carry out a new risk assessment of BPA?

In February 2012, EFSA’s expert Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) decided that the publication of new scientific research on BPA in recent years meant a full re-evaluation of the chemical was necessary. Experts on EFSA’s CEF Panel decided to undertake a full re-evaluation of the human risks from exposure to BPA through the diet, also taking into consideration the contribution of non-dietary sources of exposure to BPA. The Panel decided also to further evaluate the possible relevance for human health of some BPA-related effects observed in test animals at low dose levels.

6. How did EFSA assess the potential human health risks of BPA?

EFSA’s risk assessment of BPA consisted of:
  1. Hazard assessment – using data from animal and human studies to identify any health hazards associated with exposure to BPA.
  2. Exposure assessment – using data on the levels of BPA present in food and in food contact material and comparing them to data on food consumption in Europe to estimate average and high level exposure to BPA from food. Data on BPA levels in and from non-food sources were combined with data on behaviour patterns to estimate non-dietary exposure to BPA.
  3. Risk characterisation – analysing the extent of the risk posed by the identified hazards to consumers at current levels of exposure to BPA – via oral ingestion, breathing in dust and exposure through the skin.

7. Are ‘hazards’ and ‘risks’ the same?

No, hazards and risks are different. A hazard is a possible threat posed to health because of the intrinsic properties of a substance, such as its capacity to damage the kidney or cause cancer. But the risk that a substance could cause a negative effect depends on:
  • how much of the substance humans are exposed to
  • the length of time of the exposure
  • when exposure occurs i.e. as a fetus, child or adult.

8. What potential health effects of BPA has EFSA identified?

Based on animal studies, high doses of BPA (hundreds of times above the TDI) are likely to cause adverse effects in the kidney and liver. BPA is also likely to have effects on the mammary glands of rodents. How these effects are caused (the ‘mechanism of action’) is not clear.
Possible effects of BPA on the reproductive, nervous, immune, metabolic and cardiovascular systems, as well as in the development of cancer are not considered likely at present but they could not be excluded. They add to the overall uncertainty about BPA-related hazards and therefore have been considered in the assessment.

9. Does this mean that BPA poses a health risk to humans?

BPA poses no health risk to consumers because current exposure to the chemical is too low to cause harm. EFSA’s scientific opinion shows the level of BPA that consumers of all ages are exposed to is well below the estimated level of safe exposure – known as the tolerable daily intake (TDI). EFSA finds there is no health concern as the highest estimates for dietary and aggregate exposure to BPA are 3-5 times lower than the TDI, depending on the age group. For all population groups, dietary exposure on its own is more than 5-fold below the TDI.

10. Why has EFSA reduced the Tolerable Daily Intake (TDI)?

The reduction of the TDI is not connected to the emergence of new health concerns about BPA. EFSA has substantially reduced the TDI because the method used to assess the risk from BPA has become more refined than the one used in evaluations carried out by the Authority between 2006 and 2011.

 

More accurate data is available now so the calculations used in the risk assessment are based on substance-specific information and less on commonly used standard default values. In addition, an extensive analysis based on new techniques shows uncertainty in the data regarding mammary gland and reproductive, metabolic, neurobehavioural and immune systems, which had to be taken into account.

11. How did EFSA’s scientists calculate the new safe level (TDI)?

In its 2015 re-evaluation of BPA, EFSA used a more refined methodology than before supported by new data. Also, EFSA’s experts quantified uncertainty about some potential effects to be able to factor them in to the risk assessment and the derivation of the tolerable daily intake (TDI).

  • Experts analysed toxicological studies and used a method known as benchmark dosing to calculate the lowest dose (called the “benchmark dose”) at which BPA causes a small adverse effect in the kidneys of mice – in this case a 10% change in the mean relative weight of the organ. This effect would occur at a dose of 8960 µg/kg bw/day.
  • Using new information on the differences in the ways in which various animal species and humans metabolise and eliminate BPA, EFSA’s experts could convert the dose that causes the adverse effect on the kidneys in mice into a human equivalent dose for humans of 609 µg/kg bw/day.
  • Normally scientists would apply an uncertainty factor of 100 to take into account the differences between species and the differences between individual persons. Derivation of the human equivalent dose meant the differences between species in metabolism and elimination were already considered, leaving an uncertainty factor of 25.
  • An extra factor of six was included to take into account the uncertainty in the database related to effects on mammary gland and reproductive, neurobehavioural, immune and metabolic systems. Experts derived this factor of six by performing a detailed uncertainty analysis based on expert judgement.
  • Thus, an overall uncertainty factor of 150 (25 × 6) was applied to the equivalent human dose of 609 µg/kg bw per day to derive the new TDI of 4 µg/kg bw/day.

12. What is a benchmark dose approach?

The benchmark dose (BMD) approach is a statistical method for estimating the dose at which a particular substance causes a small but measurable effect on a certain organ in the body, e.g. a 5% change in the weight of a kidney or a 10% increase in the incidence of toxicity in the liver.  This baseline value – known as a reference point – is used for establishing a health-based guidance value such as a TDI.

 

The BMD is recognised to be a more accurate and sophisticated method for calculating a health-based guidance value because it uses all the data generated by a study rather than a single reference point.

13. Why is EFSA setting a temporary TDI (t-TDI) for BPA?

The TDI is temporary (t-TDI) pending the outcome of an on-going long-term study in rats involving prenatal as well as postnatal exposure to BPA. Research by the US National Toxicology Program (NTP) will address many of the remaining uncertainties about the potential health effects of BPA.

14. What is a weight of evidence approach?

A weight of evidence (WOE) approach assesses the strengths and weaknesses of experimental data or a study in being able to provide a scientifically rigorous answer to a specific question.

In EFSA’s 2015 opinion on BPA, this approach estimated the degree to which the newly considered evidence strengthened or weakened the likelihood of an association between BPA exposure and a certain health hazard. The conclusions of earlier assessments of BPA by EFSA in 2006 and/or 2010 were taken as the starting point for the new evaluation. EFSA assessed the strength of the evidence linking BPA to each hazard and graded them on a six-point sliding scale. This ranged from ‘very likely’ and ‘likely’, to signify the strongest links, to ‘unlikely’ and ‘very unlikely’ where the link was considered weakest. EFSA said that only those health hazards evaluated as having a likely or very likely link to BPA exposure would be considered directly in characterising the risk posed by the chemical.

15. Is BPA an “endocrine disruptor”?

Endocrine disruptors are “endocrine active substances” that can be shown to cause adverse effects by interacting or interfering with the endocrine (hormonal) system. EFSA endorses the World Health Organization’s definition that a substance must meet three criteria to be considered an endocrine disruptor:
  • firstly, the presence of an adverse effect;
  • second, the presence of endocrine activity; and
  • thirdly, a causal relationship between the two.

In their 2015 opinion on BPA, EFSA’s experts reviewed all literature on potential endocrine-related effects of BPA. They concluded that there is no single clearly-defined explanation that substantially completes scientific understanding of the potential effects of BPA in humans. Therefore, based on the WHO criteria, it is not possible to conclude that BPA is an endocrine disruptor.

BPA is one of a number of chemicals that may have the potential to interact with hormone systems in the body. It has been known since the 1930s that BPA can mimic the female sex hormone, oestrogen. The effects of BPA on fertility and reproduction and the endocrine system have been subject to much scientific debate.

16. Does BPA cause “low-dose effects”?

BPA’s potential for endocrine activity is often linked to reports of "low-dose effects" or non-monotonic dose-response relationships (NMDR) of BPA. In toxicity testing on animals, a conventional "monotonic dose-response" shows a consistent increase in (adverse) effects along the dose range. The slope of a NMDR curve, however, changes direction along the dose interval studied resulting, for example, in U-shaped or inverted U-shaped curves. Low dose effects are non-monotonic responses occurring at lower doses than those used in regulatory toxicity studies.

Based on scientific criteria, EFSA’s experts concluded that the available data do not provide evidence that BPA results in non-monotonic dose-response relationships for the health effects considered.

17. What is important about EFSA’s latest assessment of BPA exposure?

This is EFSA’s first review of consumer exposure to BPA since 2006 and the first to cover both dietary and non-dietary sources (for example, thermal paper and environmental sources such as air and dust). EFSA’s exposure assessment also considers more specific groups of the population than in its previous exposure assessment. For example, these groups include breastfed infants, bottle-fed infants, infants up to 5 days, 3 months, 6 months and 12 months old, teenagers (10-18 years) and women of child-bearing age (18-45 years).

Data on BPA levels in food were combined with figures for food consumption (including human milk) to estimate dietary exposure. Since this exposure assessment also considers non-dietary sources of exposure, data on levels of BPA in and from non-food sources (including dust, thermal paper and cosmetics) were combined with data on behaviour patterns. In addition, the results of biomonitoring (that is, analysis of BPA levels in human urine) were used to corroborate the estimates derived from data modelling, which were found to be consistent.

18. How high is consumer exposure to BPA?

  • The highest estimates for dietary exposure and for exposure from a combination of sources (called “aggregated exposure”) are three to five times lower than the t-TDI of four micrograms per kilogram of body weight per day (4 µg/kg of bw/day).
  • Dietary exposure is from four to 15 times lower than previously estimated by EFSA in 2006, depending on the age group considered. This is due to better data and less conservative assumptions for the exposure calculations.
  • Dietary exposure to BPA is highest among infants and toddlers. The highest estimates are 4 and a half times below the t-TDI. This is explained by their higher food consumption on a body weight basis.
  • Dietary exposure for bottle-fed infants aged 0-6 months is 50-fold below the t-TDI for the highest estimates.
  • Aggregated exposure, which reflects the summated exposure to the toxicologically relevant form of BPA – known as ‘unconjugated BPA’ – through all routes (diet, dust, cosmetics and thermal paper), is highest for adolescents at over 1 µg/kg bw/day.

19. What are the main sources of consumer exposure to BPA?

  • Canned food and non-canned meat and meat products are major contributors to dietary BPA exposure for all age groups. Canned food is known to be a dietary source of BPA because of the substance’s use in the lining of cans.
  • BPA might be present in meat and meat products through contact with packaging, processing equipment or through other forms of contamination (e.g. environment, feed). However, EFSA’s experts have not seen any firm scientific evidence to support this.
  • Exposure to BPA in thermal paper through the skin is the second largest source of external exposure in all age groups above three years of age, ranging from 4-fold to 8-fold below the t-TDI.

20. Were there any uncertainties in EFSA’s assessment of exposure to BPA?

There is a lack of supporting data on dermal (skin) exposure – for example, how much BPA the body absorbs through skin by touching thermal paper. This increases the uncertainty of the exposure estimates from thermal paper and cosmetics.

The uncertainty around dietary exposure is relatively low.

21. Why are the estimates of dietary exposure from 2006 and 2015 so different?

In 2006, estimates of dietary exposure to BPA were far higher due to the lack of data at that time, which led to very conservative assumptions about possible BPA levels in food and drinks. Following a call for data in 2012, EFSA reviewed over 2,500 samples to assess BPA levels in a range of food categories. In addition, EFSA can now call on its Comprehensive European Food Consumption Database, first made available in 2010, for a more detailed picture of food consumption patterns in Europe than that which existed at the time of EFSA’s previous exposure assessment of BPA. These new data have led to a considerable refinement of exposure estimates compared to 2006.

22. Is exposure to BPA from till/cash register receipts a concern?

For population groups above three years of age thermal paper (commonly used for till/cash register receipts) was the second most important source of BPA exposure after the diet, potentially accounting for up to 75% of total exposure for adolescents. Due to uncertainties around the estimates of exposure, EFSA’s experts consider more data are needed (especially related to BPA skin absorption and cash receipt handling habits) to perform a more refined estimate of exposure through this source.

23. How did EFSA quantify remaining uncertainties about BPA toxicity and exposure?

EFSA’s experts used new methodologies to take account of the uncertainties regarding potential health effects, exposure estimates and evaluation of risks for humans. By analysing each uncertainty one by one and combining the Panel’s expert judgement, EFSA’s experts were able to quantify these uncertainties and to factor them in to its risk assessment and derivation of the TDI.

24. How open and transparent was EFSA during its latest review of BPA?

Given the high level of public interest in this work and to be as open and transparent as possible, EFSA thoroughly consulted and engaged with national authorities and stakeholders during this risk assessment to ensure the widest possible range of scientific views and information were considered.

EFSA held a two-stage public consultation: in July 2013 on EFSA’s draft assessment of exposure to BPA, and in January 2014 on its draft assessment of the human health risks posed by exposure to BPA.

The results of both consultation phases as well as EFSA’s responses to the comments received are available in a report published together with EFSA’s 2015 opinion.

25. Did EFSA work together with risk assessors in Member States while developing its scientific opinion?

Whenever EFSA carries out a risk assessment it informs and engages with the competent EU Member State authorities and other partners. For example, while developing its 2015 on BPA in foodstuffs, EFSA and the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) discussed their respective assessments of BPA. The two agencies agreed that most differences concern the relevance of certain studies and the interpretation of uncertainties regarding potential human health effects of BPA. Both agencies are committed to working closely together on future risk assessments of BPA when new information is available.

26. What are the main differences between the draft and final versions of EFSA’s opinion?

The most important changes to EFSA’s opinion following the public consultations are:

  • The refinement of the reference point used for derivation of the temporary TDI by (1) recalculating the critical dose for kidney effects in mice based on the availability of individual data from the key study, and (2) use of a more refined factor to convert this dose into an oral human equivalent dose
  • Quantification and factoring in of uncertainty regarding other potential health effects, exposure estimates and evaluation of risks for humans
  • A reduction from 30% to 10% of estimated skin absorption of BPA to compare with biomonitoring data (BPA levels in human urine)
  • Assessment of risk is from dietary sources instead of all "oral" sources (i.e. dietary plus dust ingestion), as well as from all sources combined (diet, dust, cosmetics and thermal paper). 

27. What is EFSA’s role? Who regulates the safe use of BPA in the food chain?

EFSA’s role in the EU food safety system is to carry out scientific risk assessment. This risk assessment will inform the decision-making of EU risk managers in the European Commission, European Parliament and Member States who regulate the safe use of BPA as a food contact material. Risk managers take account of scientific risk assessment and other factors when making risk management decisions. These other considerations are outside EFSA’s remit as defined by European law.